Lv4
680 积分 2022-02-15 加入
A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity
1个月前
已完结
Tonic signaling in CAR-T therapy: the lever long enough to move the planet
1个月前
已完结
Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies
2个月前
已完结
STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors
4个月前
已完结
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
5个月前
已完结
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
5个月前
已完结
皖公网安备34019202002308
